Artizan Biosciences
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.
Artizan Biosciences has raised $1.5M across 1 round. Its most recent round was a Venture - Series Unknown of $1.5M in Nov 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Artizan Biosciences is featured in
Similar companies
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Neok Bio is a biotech startup that focuses on bispecific ADCs in cancer therapy.
TORL BioTherapeutics is a clinical-stage biopharmaceutical business.
ThirdLaw Molecular pioneers revolutionary Spiroligomer™ molecules for safer, more targeted, effective disease treatment.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
Weike Bio is a gene therapy drug development company.
Twinpig Biolab researches and develops anticancer drugs.
Kunshi Biotechnology is a drug developer with an emphasis on solid tumor cells.
BOOST Pharma develops a stem cell therapy for the treatment of osteogenesis imperfecta.
Step Pharma is a biotechnology company.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.